Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Qiagen ( (QGEN) ) has shared an update.
Qiagen has disclosed that the Dutch financial regulator AFM informed the company of a substantial shareholding notification filed by BlackRock, Inc. on February 24, 2026, relating to transactions dated February 20, 2026. According to the AFM register, BlackRock holds a total capital interest of 11.01% and voting rights of 12.06% in Qiagen, via a complex structure of direct equity positions and derivative contracts held through multiple BlackRock-affiliated entities, underscoring the significant role of institutional investors in Qiagen’s shareholder base and governance.
The most recent analyst rating on (QGEN) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. is a Netherlands-based life sciences company specializing in sample and assay technologies for molecular diagnostics, applied testing, academic research and pharmaceutical development. Its shares are listed on major European exchanges including Frankfurt and several regional German markets, as well as on the NYSE and Swiss exchanges, giving it broad international investor access.
Average Trading Volume: 2,103,103
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.03B
Learn more about QGEN stock on TipRanks’ Stock Analysis page.